Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells

[1]  V. Gotzos,et al.  A quantitative microdensitometric and autoradiographic study of the effect of 4′-demethyl-epipodophyllotoxin-β-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts , 1979, The Histochemical Journal.

[2]  A. Look,et al.  Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[3]  R. Giavazzi,et al.  Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma , 2004, Cancer Chemotherapy and Pharmacology.

[4]  W. Ross,et al.  Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. , 1986, Cancer research.

[5]  P. Twentyman,et al.  Identification of a novel calcium‐binding protein (CP22) in multidrug‐resistant murine and hamster cells , 1986, FEBS letters.

[6]  M. Center,et al.  Evidence for the involvement of two distinct membrane proteins in adriamycin resistance in Chinese hamster lung cells. , 1985, Cancer research.

[7]  L. Liu,et al.  Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. , 1985, Cancer research.

[8]  T. Tsuruo,et al.  Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker. , 1985, Cancer treatment reports.

[9]  W. Ross,et al.  Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. , 1985, Cancer research.

[10]  V. Ling,et al.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Barbich,et al.  DNA-mediated transfer of actinomycin D resistance into cultured mouse cells. , 1985, Experimental cell research.

[12]  B. Spengler,et al.  Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells , 1985, The Journal of cell biology.

[13]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[14]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[15]  M. Center,et al.  Involvement of plasma membrane lipid structural order in adriamycin resistance in Chinese hamster lung cells. , 1984, Cancer research.

[16]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[17]  W. Ross,et al.  Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. , 1984, Cancer research.

[18]  A. Minocha,et al.  Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. , 1984, Biochemical and biophysical research communications.

[19]  D. Roberts,et al.  Selection and characterization of L1210 sublines resistant to teniposide (VM-26). , 1984, Cancer research.

[20]  R. Gupta,et al.  4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities. , 1984, Journal of the National Cancer Institute.

[21]  Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells. , 1984, Cancer research.

[22]  B. Dahllöf,et al.  Resistance to actinomycin D and to vincristine induced in a SEWA mouse tumor cell line with concomitant appearance of double minutes and a low molecular weight protein. , 1984, Experimental cell research.

[23]  A. Ramu,et al.  Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells. , 1984, Cancer treatment reports.

[24]  G. Reaman,et al.  5'-Nucleotidase activity and arachidonate metabolism in doxorubicin sensitive and resistant P388 cells. , 1984, British Journal of Cancer.

[25]  M. Brattain,et al.  Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. , 1984, Biochemistry.

[26]  V. Ling,et al.  Co-amplification of double minute chromosomes, multiple drug resistance, and cell surface P-glycoprotein in DNA-mediated transformants of mouse cells , 1984, Molecular and cellular biology.

[27]  W. Evans,et al.  Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts. , 1983, Cancer research.

[28]  Biedler Jl,et al.  Drug resistance in Chinese hamster lung and mouse tumor cells. , 1983 .

[29]  W. T. Beck.  Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. , 1983, Cancer treatment reports.

[30]  A. Ramu,et al.  Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells. , 1983, Cancer treatment reports.

[31]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[32]  J. Ducore,et al.  Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. , 1983, Cancer research.

[33]  R. Gupta.  Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213. , 1983, Cancer research.

[34]  A. Sartorelli,et al.  The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells. , 1983, The Journal of biological chemistry.

[35]  B. Spengler,et al.  Drug resistance in Chinese hamster lung and mouse tumor cells. , 1983, Cancer treatment reports.

[36]  S. Crooke,et al.  In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). , 1982, Cancer research.

[37]  D. Kessel,et al.  Membrane alterations associated with progressive adriamycin resistance. , 1982, Biochemical pharmacology.

[38]  M. Center,et al.  Alterations in cell surface membranes in chinese hamster lung cells resistant to adriamycin , 1982 .

[39]  J. L. Biedler,et al.  Increased synthesis of a low molecular weight protein in vincristine-resistant cells. , 1981, Biochemical and biophysical research communications.

[40]  S. Hilliard,et al.  Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs. , 1980, Cancer research.

[41]  R. B. H. Gradwohl,et al.  Gradwohl's Clinical Laboratory Methods and Diagnosis , 1980 .

[42]  P. Dean.  A SIMPLIFIED METHOD OF DNA DISTRIBUTION ANALYSIS , 1980, Cell and tissue kinetics.

[43]  W. T. Beck,et al.  Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. , 1979, Cancer research.

[44]  T. Skovsgaard.  Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.

[45]  L. Allen.  Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell. , 1978, Cancer research.

[46]  G. Poschmann,et al.  Effects of the epipodophyllotoxin derivative VM 26 in mitosis and in interphase. , 1978, Oncology.

[47]  M. Hacker,et al.  VM26-induced changes in hepatic intermediary metabolism of mice. , 1977, Cancer research.

[48]  J. Loike,et al.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. , 1976, Biochemistry.

[49]  B. Barlogie,et al.  Age-dependent survival and cell-cycle progression of cultured cells exposed to chemotherapeutic drugs. , 1976, Cancer treatment reports.

[50]  H. Stähelin.  Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect. , 1976, European journal of cancer.

[51]  A. Krishan,et al.  Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts , 1975, The Journal of cell biology.

[52]  A Krishan,et al.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining , 1975, The Journal of cell biology.

[53]  D. Roberts,et al.  Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle. , 1975, Cancer research.

[54]  D. Roberts,et al.  Delayed toxicity of 4'-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) in mice. , 1973, Cancer chemotherapy reports.

[55]  H. Stähelin.  [Chemistry and mode of action of podophyllin derivatives]. , 1972, Planta medica.

[56]  J. Perez-Garcia,et al.  Inhibition of NADH-linked respiration with the anti-cancer agent 4'-demethyl-epipodophyllotoxin thenylidene glucoside (VM-26). , 1972, European journal of cancer.

[57]  Bosmann Hb.  Mechanism of cellular drug resistance. , 1971 .

[58]  H. Bosmann.  Mechanism of Cellular Drug Resistance , 1971, Nature.

[59]  D. Kessel,et al.  On the characteristics of actinomycin D resistance in L5178Y cells. , 1970, Cancer research.

[60]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[61]  H. Stähelin.  4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. , 1970, European journal of cancer.

[62]  K. Weber,et al.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. , 1969, The Journal of biological chemistry.